The application of both trastuzumab and pertuzumab in combination (but not the use of pertuzumab alone) enhanced the pathological complete response rates (pCR) from 29 to 46% with locally advanced, inflammatory, or early-stage HER2-positive breast cancer as demonstrated by the NeoSphere2 trial [12] . Nevertheless, long term monitoring is still needed to assess the capability of the two antibody based treatment regimens to delay or even prevent distant relapse and to determine the overall survival benefit. This evidence concerns the gene ERBB2 and breast carcinoma.